Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies

N Alipanah, L Jarlsberg, C Miller, NN Linh… - PLoS …, 2018‏ - journals.plos.org
Background Incomplete adherence to tuberculosis (TB) treatment increases the risk of
delayed culture conversion with continued transmission in the community, as well as …

Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis

JA Caminero, G Sotgiu, A Zumla… - The Lancet infectious …, 2010‏ - thelancet.com
Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are generally
thought to have high mortality rates. However, many cases can be treated with the right …

Delamanid for multidrug-resistant pulmonary tuberculosis

MT Gler, V Skripconoka… - … England Journal of …, 2012‏ - Mass Medical Soc
Background Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new
antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro …

Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis

NR Gandhi, P Nunn, K Dheda, HS Schaaf, M Zignol… - The Lancet, 2010‏ - thelancet.com
Although progress has been made to reduce global incidence of drug-susceptible
tuberculosis, the emergence of multidrug-resistant (MDR) and extensively drug-resistant …

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients

SD Ahuja, D Ashkin, M Avendano, R Banerjee… - 2012‏ - journals.plos.org
Background Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic,
expensive, and has generally poor outcomes. We undertook an individual patient data meta …

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

D Falzon, E Jaramillo, HJ Schünemann, M Arentz… - 2011‏ - publications.ersnet.org
The production of guidelines for the management of drug-resistant tuberculosis (TB) fits the
mandate of the World Health Organization (WHO) to support countries in the reinforcement …

Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement

C Lange, I Abubakar, JWC Alffenaar, G Bothamley… - 2014‏ - publications.ersnet.org
The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR)
tuberculosis (TB) substantially challenges TB control, especially in the European Region of …

Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis

A Van Deun, AKJ Maug, MAH Salim… - American journal of …, 2010‏ - atsjournals.org
Rationale: Based on expert opinion, the global guidelines for management of multidrug-
resistant tuberculosis impose lengthy and often poorly tolerated treatments. Objectives: This …

[HTML][HTML] New drugs and perspectives for new anti-tuberculosis regimens

S Tiberi, M Muñoz-Torrico, R Duarte, M Dalcolmo… - Pulmonology, 2018‏ - Elsevier
Tuberculosis (TB) is the ninth cause of global death, more than any other infectious disease.
With growing drug resistance the epidemic remains and will require significant attention and …

Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes

D Falzon, N Gandhi, GB Migliori… - European …, 2013‏ - publications.ersnet.org
A meta-analysis for response to treatment was undertaken using individual data of multidrug-
resistant tuberculosis (MDR-TB)(resistance to isoniazid and rifampicin) patients from 26 …